个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Jiang, L.[1] * ; Zheng, D.[2] ; Ni, J.[2] ; Ding, H.[3] ; Zhao, Y.[1] ; Heng, W.[4] ; Shang, Y.[5] ; Cai, X.[1] ; Yan, J.[6] ; Wang, J.[2] ; Guo, J.[1] ; Tan, X.[7] ; Hong, X.[8] ; Zhang, J.[9] ;
机构： [1]Shanghai Chest Hosp, Shanghai, Peoples R China [2]Shanghai Pulm Hosp, Shanghai, Peoples R China [3]Zhenjiang First Peoples Hosp, Zhenjiang, Peoples R China [4]Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China [5]Hebei Univ, Affiliated Hosp, Baoding, Peoples R China [6]Hebei Petro China Ctr Hosp, Langfang, Peoples R China [7]Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai, Peoples R China [8]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [9]Shanxi Bethune Hosp, Taiyuan, Peoples R China
出处：
ISSN：

关键词： Paclitaxel liposome Immunotherapy Non-small cell lung cancer

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2025]版：
无
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2024]版：
无
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2024版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Shanghai Chest Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Jiang L.,Zheng D.,Ni J.,et al.Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study[J].JOURNAL OF THORACIC ONCOLOGY.2024,19(10):S248-S249.
APA：
Jiang, L.,Zheng, D.,Ni, J.,Ding, H.,Zhao, Y....&Zhang, J..(2024).Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study.JOURNAL OF THORACIC ONCOLOGY,19,(10)
MLA：
Jiang, L.,et al."Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study".JOURNAL OF THORACIC ONCOLOGY 19..10(2024):S248-S249

相关文献

[1]Baseline 18F-FDG PET/CT parameters in predicting the efficacy of immunotherapy in non-small cell lung cancer [2]Application of radiomics based on chest CT-enhanced dual-phase imaging in the immunotherapy of non-small cell lung cancer [3]Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review [4]Transformation from non-small cell lung cancer to small cell lung cancer: A report of clinicopathological characteristics and prognoses. [5]miR-374a-5p inhibits non-small cell lung cancer cell proliferation and migration via targeting NCK1 [6]非小细胞肺癌免疫相关生物标志物的研究进展 [7]Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report [8]lncRNA PDIA3P regulates cell proliferation and invasion in non-small cell lung cancer [9]Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration [10]microRNA-448 inhibits the progression of non-small-cell lung cancer through regulating IRS2

资源点击量：15101 今日访问量：1 总访问量：961 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持：重庆聚合科技有限公司 地址：保定市莲池区裕华东路212号